ResMed has secured FDA clearance for its Smart Comfort therapy, enhancing its position as a leader in AI integration within the sleep apnea treatment market. The company's ability to capture over 80% of new CPAP sales following competitor Phillips' recall further underscores its dominance. Recent quarterly earnings of $1.35 billion exceeded analyst forecasts, reflecting a strong growth trajectory with a 12% CAGR, despite receiving a neutral rating downgrade from Baird. UBS, however, raised its price target on ResMed, suggesting continued investor confidence in the company's innovative advancements.
“Resmed · received · FDA clearance for Personalized Therapy Comfort Settings · Smart Comfort”
“Resmed · creates · life-changing health technologies · empowering millions of people in 140 countries”
“ResMed · traces its roots back to · 1989 · Australia”
“Resmed · is a company valued at · $5 billion+ · true”
“Resmed · is growing at · 12% 5-year CAGR · true”
“Resmed · has done an incredible job monetizing · sleep apnea · true”
“Resmed · believes the industry now faces · a new paradigm · true”
“Resmed believes · the industry now faces · a new paradigm · to improve top-of-the-funnel conversion”
“Resmed argues · more people going to sleep doctors · is incrementally positive · to the conversion story”
“40% of current users · have · mild sleep apnea · according to Resmed”
“the FDA · granted · Resmed a monopoly”
“Resmed · has taken · over 80% of the new CPAP sales”
